ERBB2 and neoplasm: To exclude the possibility that the failure of antibody-containing regimens to inhibit HER2 signaling and tumor cell proliferation is likely due to shorter treatment duration, and to ensure buildup of sufficient and stable plasma drug levels, we conducted a second short-term study to test whether an extended pre-treatment with the antibodies will promote their anti-tumor efficacy.